TransMedics Group (TransMedics Group) Interest Expense : $-13.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TransMedics Group's interest expense for the three months ended in Mar. 2024 was $ -3.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TransMedics Group's Operating Income for the three months ended in Mar. 2024 was $ 12.4 Mil. TransMedics Group's Interest Expense for the three months ended in Mar. 2024 was $ -3.6 Mil. TransMedics Group's Interest Coverage for the quarter that ended in Mar. 2024 was 3.45. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TransMedics Group Interest Expense Historical Data

The historical data trend for TransMedics Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Interest Expense Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.35

-3.99

-3.87

-3.73

-10.79

TransMedics Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.09	-2.51	-3.59	-3.61	-3.60

TransMedics Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.3 Mil.

TransMedics Group (NAS:TMDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TransMedics Group's Interest Expense for the three months ended in Mar. 2024 was $-3.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was $12.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $514.1 Mil.

TransMedics Group's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	12.421	/	-3.598
	=	3.45

The higher the ratio, the stronger the company's financial strength is.

TransMedics Group (TransMedics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

8T8:Germany TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.

Executives

Tamer I Khayal	officer: Chief Commercial Officer	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost	officer: VP of US Regulatory & FDA Rel.	2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein	director, officer: President & CEO	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon	officer: Chief Financial Officer	200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill	director	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile	director	200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey	officer: VP of Operations	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme	officer: VP, Clinical Affairs	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr	director
Rakesh P. Godhani	officer: Chief Digital Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan	officer: VP of Quality & Engineering	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810